A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2

NCT02649556 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 672

Last updated 2020-12-04

Study results available
· View outcomes & findings →

Summary

The objective of the ZRHR-ERS-09-EXT-US study is to further assess the effect of the Tobacco Heating System 2.2 (THS 2.2), a candidate Modified Risk Tobacco Product, compared to conventional cigarettes (CC) on the components of the "smokers' health profile" for a prolonged period of 26 weeks, providing additional information to the results of the original study ZRHR-ERS-09-US of 26-week exposure (NCT02396381). In total, the ZRHR-ERS-09-EXT-US study will extend the exposure period to 52 weeks.

Conditions

  • Smoking

Interventions

OTHER

THS 2.2

Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.

OTHER

CC

Ad libitum use of CC in an ambulatory setting for 26 weeks. The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product.

Sponsors & Collaborators

  • Philip Morris Products S.A.

    lead INDUSTRY

Principal Investigators

  • Christelle Haziza, PhD · Philip Morris Products S.A.

  • Danielle Armas, MD · Celerion Arizona

  • Leonard Dunn, MD · Clinical Research West Florida

  • Hugh Coleman, MD · Covance

  • George Stoica, MD · Compass Research

  • Mark Adams, MD · Central Kentucky Research Associate

  • Peter Davidson, MD · Celerion Lincoln

  • John Rubino, MD · PMG Research of Raleigh

  • George Raad, MD · PMG Research of Charlotte

  • Kevin Cannon, MD · PMG Research of Wilmington

  • Derek Schroder, MD · PMG Research of Cary

  • Stephanie Powell, MD · PMG Research of Bristol

  • William Smith, MD · NOCCR

  • Darrell Herrington, MD · Benchmark

  • Laurence Chu, MD · Benchmark

  • William Seger, MD · Benchmark

  • David Subich, MD · Compass Research

  • Lon Lynn, MD · Clinical Research West Florida

  • Isabel Kuhare-Arcure, MD · Midwest Clinical Research

  • Keith Scott, MD · National Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-03-13
Completion
2017-12-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02649556 on ClinicalTrials.gov